Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Vaccination and immunotherapies in neuroimmunological diseases
Alexander Winkelmann, Micha Loebermann, Michael Barnett, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 5, pp. 289-306
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Somatosensory cortex and central amygdala regulate neuropathic pain-mediated peripheral immune response via vagal projections to the spleen
Xia Zhu, Ji-Ye Huang, Wanying Dong, et al.
Nature Neuroscience (2024) Vol. 27, Iss. 3, pp. 471-483
Closed Access | Times Cited: 14
Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis
Maria‐Ioanna Stefanou, Lina Palaiodimou, Aikaterini Theodorou, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 4-5, pp. 585-594
Open Access | Times Cited: 33
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
Susana Otero‐Romero, Christine Lebrun‐Frénay, Saúl Reyes, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 8, pp. 904-925
Open Access | Times Cited: 29
B cell targeted therapies in inflammatory autoimmune disease of the central nervous system
Moritz J. Furman, Sven G. Meuth, Philipp Albrecht, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments
Lucian Eva, Horia Pleș, Razvan-Adrian Covache-Busuioc, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2489-2489
Open Access | Times Cited: 16
The CXCL13 index biomarker predicts success or failure of moderate-efficacy disease-modifying therapies in multiple sclerosis; a real-world study
Andrew R. Pachner, Steven C. Pike, Andrew D. Smith, et al.
Multiple Sclerosis and Related Disorders (2025), pp. 106303-106303
Closed Access
Engineered immunological niche directs therapeutic development in models of progressive multiple sclerosis
Laila M. Rad, Kevin R. Hughes, Sydney N. Wheeler, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 7
Open Access
Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization
René Carvajal, Carmen Tur, Blanca Borrás-Bermejo, et al.
Multiple Sclerosis Journal (2025)
Closed Access
European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
Susana Otero‐Romero, Christine Lebrun‐Frénay, Saúl Reyes, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 8, pp. 2144-2176
Open Access | Times Cited: 12
Therapeutic potential of natural killer cells in neuroimmunological diseases
Qing Zhang, Jing Lin, Mengge Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116371-116371
Open Access | Times Cited: 3
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab
René Carvajal, Ana Zabalza, Pere Carbonell‐Mirabent, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e246345-e246345
Open Access | Times Cited: 3
Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases
Michael Hecker, Niklas Frahm, Paula Bachmann, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study
Niklas Frahm, Firas Fneish, David Ellenberger, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 11, pp. 3640-3640
Open Access | Times Cited: 7
TREM-2 Drives Development of Multiple Sclerosis by Promoting Pathogenic Th17 Polarization
Siying Qu, Shengfeng Hu, Huiting Xu, et al.
Neuroscience Bulletin (2023) Vol. 40, Iss. 1, pp. 17-34
Closed Access | Times Cited: 6
Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation
Uwe K. Zettl, Paulus Rommer, Orhan Aktaş, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 11, pp. 1343-1359
Open Access | Times Cited: 6
Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
Federica Dominelli, Maria Antonella Zingaropoli, Matteo Tartaglia, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with disease-modifying therapies in Poland
Aleksandra Podlecka‐Piętowska, Janusz Sierdziński, Monika Nojszewska, et al.
Neurologia i Neurochirurgia Polska (2024) Vol. 58, Iss. 1, pp. 112-119
Open Access | Times Cited: 1
Infektionen und Multiple Sklerose
Felicita Heidler, Tobias Bopp, Matthias Schwab, et al.
Fortschritte der Neurologie · Psychiatrie (2024)
Closed Access | Times Cited: 1
Association between vaccination and the risk of central demyelination: results from a case-referent study
Lamiae Grimaldi‐Bensouda, Caroline Papeix, Yann Hamon, et al.
Journal of Neurology (2023) Vol. 270, Iss. 10, pp. 4678-4686
Open Access | Times Cited: 4
New consensus guidelines on vaccination in multiple sclerosis
Uwe K. Zettl, Paulus Rommer
Nature Reviews Neurology (2023) Vol. 19, Iss. 9, pp. 509-510
Closed Access | Times Cited: 4
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
Maura Pugliatti, Hans‐Peter Hartung, Celia Oreja‐Guevara, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic
Felicita Heidler, Julia Baldt, Niklas Frahm, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 6
Association between infections, the microbiome, vaccination, and neuromyelitis optica spectrum disorder
Edgar Carnero Contentti, Jorge Correale
Multiple Sclerosis Journal (2022) Vol. 29, Iss. 4-5, pp. 492-501
Closed Access | Times Cited: 5
Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk
Maria Antonella Zingaropoli, Patrizia Pasculli, Matteo Tartaglia, et al.
Biology (2023) Vol. 12, Iss. 4, pp. 587-587
Open Access | Times Cited: 2
Living virus‐based nanohybrids for biomedical applications
Lulu Jin, Zhengwei Mao
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top